دورية أكاديمية

MRTX-500 Phase 2 Trial: Sitravatinib With Nivolumab in Patients With Nonsquamous NSCLC Progressing On or After Checkpoint Inhibitor Therapy or Chemotherapy

التفاصيل البيبلوغرافية
العنوان: MRTX-500 Phase 2 Trial: Sitravatinib With Nivolumab in Patients With Nonsquamous NSCLC Progressing On or After Checkpoint Inhibitor Therapy or Chemotherapy
المؤلفون: He, Kai, Berz, David, Gadgeel, Shirish M., Iams, Wade T., Bruno, Debora S., Blakely, Collin M., Spira, Alexander I., Patel, Manish R., Waterhouse, David M., Richards, Donald A., Pham, Anthony, Jotte, Robert, Hong, David S., Garon, Edward B., Traynor, Anne, Olson, Peter, Latven, Lisa, Yan, Xiaohong, Shazer, Ronald, Leal, Ticiana A.
المصدر: In Journal of Thoracic Oncology July 2023 18(7):907-921
قاعدة البيانات: ScienceDirect
الوصف
تدمد:15560864
DOI:10.1016/j.jtho.2023.02.016